Dynamic Evaluation of Myocardial Fibrosis and Structural Determinants of Ventricular Arrhythmia in Mitral Valve Prolapse (STAMP-2 : STretch and Myocardial Characterization in Arrythmogenic Mitral Valve Prolapse-2)

What this Trial Is About

Mitral valve prolapse (MVP) is a common condition affecting the mitral valve, with a prevalence of 2-3% in the general population. While often considered benign, MVP can progress to mitral valve regurgitation and rhythm disturbances. Researchers are evaluating factors that may predict unfavorable outcomes such as ventricular remodeling or arrhythmias over three years in patients with MVP. This study is led by the Central Hospital in Nancy, France, and uses imaging and biomarkers to better understand the condition's progression. Participants are divided into groups based on the severity of mitral regurgitation and presence of ventricular extrasystoles. All will have assessments at the start and after 36 months, including recommended tests like echocardiography, 24-hour external loop recording, and exercise ECG. For research purposes, they will also undergo injected cardiac MRI with additional MRI sequences (4D flow) and blood collections, including genetics, to study myocardial changes and arrhythmia risks. Throughout the study, participants will be closely monitored with imaging and rhythm evaluations to track ventricular remodeling and arrhythmia occurrence. The main outcomes measured include the presence of ventricular remodeling and ventricular arrhythmias such as fibrillation, tachycardia, or extrasystoles at three years. This research involves no randomization or blinding, and participants are expected to undergo detailed testing at two timepoints over the three-year period.

STretch and Myocardial Characterization in Arrythmogenic Mitral Valve Prolapse-2